mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane(Basilea Pharmaceutica (Switzerland)), Terence O’Reilly(Novartis (Switzerland))
Cited by 251
Related Papers
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
|Nature Medicine|2004|956
Effective <i>in vivo</i> targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
|Molecular Cancer Therapeutics|2008|128
Validation of a Postfixation Tissue Storage and Transport Medium to Preserve Histopathology and Molecular Pathology Analyses (Total and Phosphoactivated Proteins, and FISH)
|American Journal of Clinical Pathology|2012|12